pipelin come view bullish prospect
pleas recent perform excit pipelin
last week met omar ishrak chairman/ceo karen parkhil evp/cfo bob
white evp pre mitg ryan weispfen vice-president ir pleas recent
perform cite ep growth last year vs long-term target ep
growth come way better revenu growth om expans improv cash
flow strive drive excel execut manag larg
portfolio shown growth improv despit larger revenu base look
forward excit product pipelin number big launch
next month encourag result robust
pipelin give us greater confid abil achiev guidanc despit
pressur area like paclitaxel/dcb steril lvad diabet pain stim
reiter buy rate share think drive msd growth near term
potenti acceler given pipelin
pipelin product progress preview fall
pipelin product launch next two year includ micra av leadless
pacer surgic robot soft tissu applic bullish
meet next-gen diabet sensor close loop system along
expans tavr label includ low risk meet think
market readi strong player soft tissu robot highlight number
area like instrument throughput cost improve/eas hospit
pain point look forward fall analyst day ou launch
margin target track offset headwind
year expect drive margin expans headwind tax
fx lead ep growth slightli ep goal despit year
optimist growth acceler come pipelin fy
valuat pt base ep estim
trade con ep april end compar pe multipl
peer like bump pt
base ep account increas confid target
potenti near-term posit fda paclitaxel panel
trade data key metric
compani account thomson reuter ub estim ub adjust ep state goodwill-rel charg adjust abnorm econom item analyst
judgement valuat base averag share price year base share price jun edt
report prepar ub secur llc analyst certif requir disclosur begin
page ub seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
mazor placement
new mazor spinal robot system well placement
first full quarter launch combin stealth/mazor platform note
mani placement competit account implant
market share lower robot give pathway drive implant
share time way implant growth lag indic mdt
success robot placement look lead edg note
spine busi includ enabl technolog grow msd
quarter sale capit like o-arm stealth also
benefit mazor launch competit spine surgeon see robot
way get board earli futur spine surgeri
bullish soft tissu robot launch track
bullish prospect soft tissu robot much learn mazor
appli soft tissu robot launch plan ou launch
analyst day fall stage market leader
instruments/end effector could give advantag also help drive
robot adopt beyond procedur see today part
approach address barrier robot surgeri like instrument cost
productivity/tim also seek improv area like visual data
one issu current robot system low util given high cost
acquir maintain perform robot procedur opportun cost
use oper
hospit current global averag util around procedur per day
number think improv significantli clearli go
account robot also one low
penetr robot today believ market readi strong
pain point
date receiv feedback hundr surgeon use
system first mover help aspect also tie one
legaci architectur like system built scratch
design surgeon input first mover
instrument year mi experi mani instrument
diabet launch toward year end close sensor gap
diabet expect close sensor gap year new sensor
launch anticip launch toward end year look
forward expect sensor technolog less differenti today
game around data analyt recent note
diabet franchis ada
cvg updat tavr micra
tavr hope gain low risk label launch new larg valv
also expect low risk tavr new ncd could lead
mani center come year continu see mitral
good opportun bigger tavr space bullish replac
although also earli stage repair invest recent tavr
survey
micra av expect launch toward end fy
redesign longer batteri life av pacer potenti open
leadless pacer market opportun today market
differenti reimburs price tradit pacer data
earli trial encourag current run pivot
trial notabl mdt share singl chamber micra launch
order implant dollar vs overal
margin target bp driven cog enterpris excel
look margin continu consolid manufactur site
way drive continu product
cog time mdt enterpris excel program aim
reduc cost function area like financ hr legal time
benchmark compani similar size area net-net
confid abil achiev goal bp margin expans
annual even reinvest
global theme drive growth innov
competit increas along scrutini healthcar cost
respond sharpen focu across board thing like portfolio
manag capit alloc cost becom import
compani grown note grow rate equal better
half size promis theme like global
econom valu remain import sens grow focu innov
product manag
lifeblood mdt growth
innov cycl come disciplin focu portfolio
right area market product achiev pathway leadership select
segment given chang healthcar made prioriti
make/deliv disrupt bet regular cadenc lead
technolog focu tough clinic problem solv attempt
invent disrupt statu quo
interstim micro launch smaller devic recharg
leverag batteri technolog fast recharg time
riptid launch go well believ gain market share
set target end fy
valuat method risk statement
price target base ep risk price
target includ slowdown core cardio neuro spine surgic end market
increas competit establish larg cap compani competit
entrant differenti technolog delay key product approv
reject regulatori bodi inabl deliv top-lin growth meet
consensu expect top line miss guidanc consensu
bottom line delay robot launch timelin mitral project meet
expect chang regulatori environ lead longer lead
time higher bar approv
report prepar ub secur llc affili ub ag ub ag subsidiari branch affili
refer herein ub
inform way ub manag conflict maintain independ research product histor
perform inform certain addit disclosur concern ub research recommend pleas visit
www ub com/disclosur figur contain perform chart refer past past perform reliabl
indic futur result addit inform made avail upon request ub secur co limit licens
conduct secur invest consult busi china secur regulatori commiss ub act may act
princip debt secur relat deriv may subject report recommend
final june pm gmt ub design certain research depart member deriv
research analyst depart member publish research princip analysi price market
deriv provid inform reason suffici upon base decis enter deriv
transact deriv research analyst co-author research report equiti research analyst economist
deriv research analyst respons deriv invest view forecast and/or recommend
analyst certif research analyst primarili respons content research report whole part
certifi respect secur issuer analyst cover report view express
accur reflect person view secur issuer prepar independ manner
includ respect ub part compens directli indirectli relat
specif recommend view express research analyst research report
fsr mra
fsr mra
fsr mra
stock price expect rise within three month time
rate assign specif catalyst event
stock price expect fall within three month time
rate assign specif catalyst event
ub rate alloc march
compani coverag global within rate categori
compani within rate categori invest bank ib servic provid
within past month
compani coverag global within short-term rate categori
compani within short-term rate categori invest bank ib servic provid
within past month
definit forecast stock return fsr defin expect percentag price appreci plu gross dividend
yield next month case yield may base accru dividend market return assumpt
mra defin one-year local market interest rate plu proxi forecast equiti risk
premium review ur stock may flag ur analyst indic stock price target and/or
rate subject possibl chang near term usual respons event may affect invest case
valuat short-term rate reflect expect near-term three month perform stock
reflect chang fundament view invest case equiti price target invest horizon
except special case uk european invest fund rate definit buy posit
factor structur manag perform record discount neutral neutral factor structur
manag perform record discount sell neg factor structur manag perform record
discount band except cbe except standard band may grant invest
review committe irc factor consid irc includ stock volatil credit spread respect
compani debt result stock deem high low risk may subject higher lower band
relat rate except appli identifi compani disclosur tabl relev
